The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Daily injection of the dopamine D(2) receptor antagonist haloperidol is associated with the development of catalepsy sensitization in rats, which leads to a day to day increase of rigor and akinesia. The process of catalepsy sensitization incorporates different learning stages. Here we investigated the mechanisms underlying the consolidation of catalepsy sensitization. In particular, we asked whether NMDA- and non-NMDA (AMPA- and Kainate) receptors play a role in the consolidation of catalepsy sensitization. Accordingly, rats received post-training injections of the NMDA receptor antagonist MK-801 (single injection of either 0.1mg/kg or 0.25mg/kg; or a double injection of 0.1mg/kg immediately and 30 min after test cessation) or of the AMPA/Kainate receptor antagonist GYKI 52466 (single injection of 5mg/kg). Our results showed that the consolidation of catalepsy sensitization was decelerated by both glutamatergic AMPA/Kainate- and NMDA-receptor antagonists. With the higher MK-801 dosage, the deceleration was stronger, suggesting a dose dependent mechanism. We hence affirmed a role for the ionotropic glutamate receptors in the consolidation process of catalepsy sensitization.
University of Tübingen, Neuropharmacology, Auf der Morgenstelle 28E, 72076 Tübingen, Baden-Wuerttemberg Germany. Katrin.Riedinger@web.de
K
K
Riedinger
A
A
Kulak
W J
WJ
Schmidt
A
A
von Ameln-Mayerhofer
D000704:Analysis of Variance; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced* / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018092:Kainic Acid Receptors / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism*
D001569:Benzodiazepines; D016291:Dizocilpine Maleate; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D006220:Haloperidol; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate; C061950:GYKI 52466